The glucose-lowering effect of low-dose diacerein and its responsiveness metabolic markers in uncontrolled diabetes.

Citation metadata

From: BMC Research Notes(Vol. 15, Issue 1)
Publisher: BioMed Central Ltd.
Document Type: Report
Length: 2,818 words
Lexile Measure: 1430L

Document controls

Main content

Abstract :

Objective Diacerein inhibits the synthesis and activity of pro-inflammatory cytokines, decreases macrophage infiltration in adipose tissue and thus increases insulin sensitivity and signalling. We conducted this study to determine the efficacy of low-dose diacerein in improving glycaemic control in type 2 diabetes mellitus (T2DM) patients with inadequate glycaemic control and to identify the metabolic determinants for such improvement. We randomised 25 T2DM patients with poor glycaemic control, despite being treated with at least three glucose-lowering agents, to receive diacerein 50 mg once-daily (n = 18) or placebo (n = 17) for 12 weeks. Changes in glycated haemoglobin (HbA1c) were evaluated at the 4th and 12th weeks. Metabolic profiling was performed using liquid chromatography electrospray ionisation quadrupole time-of-flight mass spectrometry. Results HbA1c levels were significantly reduced from baseline in the diacerein group at 12 weeks (- 0.6%, p Retrospective trial registration Current Controlled Trials TCTR20200820004, 20 August 2020. Keywords: Diacerein, Type 2 diabetes, Metabolomics, Glycemic control, Inflammation

Source Citation

Source Citation   

Gale Document Number: GALE|A699501086